Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results

LLY is one of the world’s most valuable healthcare companies, creating medicines for diabetes, oncology, immunology, neuroscience, and obesity, along with using advanced technologies and AI to make more treatments. The company’s first-quarter fiscal 2026 earnings report, LLY showed $19.8 billion in quarterly revenue (a 56% year-over-year gain) led by its Zepbound and Mounjaro products ($12.8 billion together) that will soon be covered by Medicare, non-GAAP per-share earnings of $8.55 (a 156% annual jump), and offered annual guidance of up to $85 billion and $37 for revenue and EPS, respectively.

It’s no wonder LLY shares are up 12% this year, and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Eli Lilly Being Bought

Institutional volumes reveal plenty. In the last year, LLY has endured some choppiness. But it’s once again enjoying strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in LLY shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly.

Eli Lilly Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, LLY has had strong sales and earnings growth:

• 3-year sales growth rate (+32.1%)
• 3-year EPS growth rate (+60.6%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +21.7%.

Now it makes sense why the stock has been generating Big Money interest. LLY has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Eli Lilly has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

In the last year, LLY has drawn five outlier inflow signals and is up 53.9%. The blue bars below show when LLY was a top pick on the Outlier 20 report…institutions remain buyers:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Eli Lilly Price Prediction

The LLY action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in LLY at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.